BOARD OF DIRECTORS

Kurt Graves

Chairman, President and CEO

Mr. Graves is a global industry leader with more than twenty years of US and global general management experience in top-tier US and European based pharmaceutical and biotech companies. He has successfully built and managed several of the largest multi-billion dollar franchises in the industry and developed and launched more than 10 blockbuster brands in a broad range of general medicine, specialty and orphan disease areas. In addition to driving dynamic top and bottom-line growth in large global pharmaceutical companies, Mr. Graves also played a key leadership role in building two highly successful early stage companies; at Astra Merck Pharmaceuticals and Vertex Pharmaceuticals. Most recently Mr. Graves served as the Executive Chairman of Intarcia Therapeutics. Prior to that Mr. Graves was EVP, Chief Commercial Officer and Head of Corporate and Strategic Development at Vertex Pharmaceuticals from 2007 through the end of 2009. Prior to his tenure at Vertex, he spent nearly ten years at Novartis Pharmaceuticals, most recently as Global Head of the General Medicines Business & Chief Marketing Officer for the Pharmaceuticals division. Prior to his tenure at Novartis, Mr. Graves held several commercial and general management positions at Merck and Astra Merck/Astra Pharmaceuticals where he spent most of his time leading the GI Business Unit responsible for Prilosec and Nexium. Mr. Graves serves as Chairman of the Board at Intarcia and Radius therapeutics and as a Director at Springleaf Therapeutics and Pulmatrix Pharmaceuticals. Mr. Graves earned his B.S. in Biology from Hillsdale College and has attended numerous executive leadership programs at Harvard, Wharton School of Management and University of Michigan.

Ed Mathers

Director

Ed Mathers joined NEA as a partner in August 2008 and is focused on biotechnology and specialty pharmaceuticals investments. Prior to joining NEA, Ed most recently served as Executive Vice President, Corporate Development and Venture, at MedImmune, Inc. In this role, he was responsible for the company's licensing and business development activities and led the company's venture capital subsidiary, MedImmune Ventures, Inc. Before joining MedImmune in 2002, he was Vice President, Marketing and Corporate licensing and Acquisitions at Inhale Therapeutic Systems. Ed spent 15 years at Glaxo Wellcome, Inc. (GlaxoSmithKline), where he held sales and marketing positions of increasing responsibility. He started his career at Ortho Pharmaceuticals Corporation, a division of Johnson & Johnson, as a researcher. Ed currently serves on the boards of several companies including Kémia, Inc., Satori and Plexxikon Inc. He earned his bachelor's degree in chemistry from North Carolina State University.

James Niedel M.D. Ph.D.

Director

James Niedel is a Managing Director of New Leaf Venture Partners, a life science venture fund. Prior to joining the venture industry in May 2002, Dr. Niedel was Chief Science and Technology Officer for GlaxoSmithKline and from 1995 to 2001 he was a member of the board of directors of Glaxo Wellcome plc with responsibility for Global Research and Development, Information Technology and Product Strategy. From 1988 to 1995 he was VP Research and SVP R&D for the US subsidiary of Glaxo. Before joining the pharmaceutical industry, Jim was Professor of Medicine and Chief of the division of Clinical Pharmacology at Duke Medical School, where he had completed an Internal Medicine residency and a Hematology-Oncology fellowship. He received the M.D. and Ph.D. (Biochemistry) degrees from the University of Miami, was selected a Searle Scholar, and is a Fellow of the Royal College of Physicians (London).

Glen Sato, J.D.

Director

Glen Sato has been a partner in the Life Sciences and Companies practice group at Cooley Godward LLP since January 2006. Prior to that time, he served as Senior Vice President and Chief Financial Officer of PDL BioPharma, Inc. (PDL) from May 2003 to September 2005. He joined PDL from Exelixis, Inc., where he had served as Chief Financial Officer and General Counsel since November 1999. Previous to Exelixis, he served in various legal and strategic planning positions at PDL, most recently as Vice President, Legal and General Counsel. During his tenure at PDL and Exelixis, Mr. Sato was responsible for finance, SEC reporting and compliance, disclosure issues and internal and external business functions, including business development, intellectual property licensing and licensing strategy, general corporate counseling, insider trading compliance and intellectual property protection. He received his Bachelor of Arts from Wesleyan University, and his J.D. and M.B.A. from UCLA.

Irwin Scher, M.D

Director

Irwin Scher, M.D. has served as a member of our board of directors since April 2005. Since March 2005, Dr. Scher has served as the Chief Executive Officer of Biosynexus, Incorporated, a biopharmaceutical company. From January 2002 to January 2005, Dr. Scher served as a full-time development and business consultant to the chief executive officer of Merck KgaA in Darmstadt, Germany, a global pharmaceutical products and services company, while also serving as Vice President, global clinical research and development for Merck KgaA from June 2002 to September 2003. From January 1992 to August 1999, Dr. Scher served as Senior Vice President, Drug Development and Medical Affairs at Astra/Merck, a joint venture of Astra AB and Merck, and AstraZeneca, a global pharmaceutical products company. Dr. Scher is a director of Clarient, Inc. Dr. Scher holds a B.S. in chemistry from the New York State University at Albany and an M.D. from the Albert Einstein College of Medicine. He is board certified in internal medicine and rheumatology.